Jim Cramer's Stop Trading: Jazz Pharmaceuticals Faces Music

NEW YORK (TheStreet) -- Jazz Pharmaceuticals (JAZZ) "did not hit the numbers, so the stock is down," TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said on CNBC's "Cramer's Stop Trading" segment. 

The company missed analysts' estimates for its top- and bottom-line results. Cramer said he's highlighting Jazz Pharmaceuticals because of how poorly biotechnology stocks have performed over the past two months.

Turning to WhiteWave Foods (WWAV), "I thought that quarter was amazing," he said of the company's top and bottom line earnings beat. 

He added that Hain Celestial Group (HAIN) is also doing very well, and its CEO Irwin Simon is "too clever" for the short-sellers.

- - Written by Bret Kenwell in Petoskey, Mich.

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

More from Opinion

Trump Blinks on China Trade War That's Looking Harder to Win

Trump Blinks on China Trade War That's Looking Harder to Win

Monday Madness: GE, China, and Micron

Monday Madness: GE, China, and Micron

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

How Technology Will Unleash the Legal Marijuana Industry's Growth Potential

How Technology Will Unleash the Legal Marijuana Industry's Growth Potential

Apple Buys Tesla? Amazon Buys Sears? 3 Dream Mergers That Just Make Sense

Apple Buys Tesla? Amazon Buys Sears? 3 Dream Mergers That Just Make Sense